Photo from wikipedia
Key Points Question What is the incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir? Findings In this cohort study of 12 629 adults in Hong Kong with COVID-19 who… Click to show full abstract
Key Points Question What is the incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir? Findings In this cohort study of 12 629 adults in Hong Kong with COVID-19 who were hospitalized and had serial cycle threshold values measured, viral rebound (defined as a cycle threshold value >40 that decreased to ≤40) occurred in 68 antiviral nonusers (0.6%), 2 (1.0%) nirmatrelvir-ritonavir users, and 6 (0.8%) molnupiravir users. Meaning In this study, viral rebound was uncommon in adults with COVID-19 after treatment with nirmatrelvir-ritonavir and molnupiravir, suggesting that these novel oral antivirals should be prescribed to more patients with COVID-19 in the early phase of the infection.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!